Evidence map›Paper›PMID 39331323›Full record

ArticleInfectious diseases and therapy2024

Letter to the Editor regarding Response to "Letter to Editor: "Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19".

Takahiro Takazono, Satoki Fujita, Takuji Komeda, Shogo Miyazawa, Yuki Yoshida, Yoshitake Kitanishi, Masahiro Kinoshita, Satoshi Kojima, Huilian Shen, Takeki Uehara and 3 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Takahiro TakazonoDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Satoki FujitaData Science Department, Shionogi & Co., Ltd., Osaka, Japan. satoki.fujita@shionogi.co.jp.
Takuji KomedaData Science Department, Shionogi & Co., Ltd., Osaka, Japan.
Shogo MiyazawaData Science Department, Shionogi & Co., Ltd., Osaka, Japan.
Yuki YoshidaData Science Department, Shionogi & Co., Ltd., Osaka, Japan.
Yoshitake KitanishiData Science Department, Shionogi & Co., Ltd., Osaka, Japan.
Masahiro KinoshitaMedical Affairs Department, Shionogi & Co., Ltd., Osaka, Japan.
Satoshi KojimaMedical Affairs Department, Shionogi & Co., Ltd., Osaka, Japan.
Huilian ShenMedical Affairs Department, Shionogi & Co., Ltd., Osaka, Japan.
Takeki UeharaDrug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan.
Naoki HosogayaDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Naoki IwanagaDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19EnsitrelvirHospitalizationJapanese nationwide database

Identifiers

PMID39331323
PMCPMC11499536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.